NCT06993883Completed
Use of Venetoclax , AML , Sohag , Egypt
Use of Venetoclax in AML Patients Retrospective Experience in Sohag Governorate , an Area of Limited Resources in Upper Egypt
Source: ClinicalTrials.gov · Last updated 29 May 2025
Brief summary (registry, in English)
retrospective observational study to evaluate the benefit of adding venetoclax to chemotherapy in the first or second line setting in Sohag governorate.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 43 (actual)
- First submitted
- 13 May 2025
- Start date
- 1 Mar 2023
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Sohag University
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT06993883
What you commit to
- Study type: Observational
- Participants enrolled: 43
- From 1 Mar 2023 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- age \< 18 years age \> 80 years other types of acute leukemia
Other
- \-
Who the study is looking for
- Patients aged between 18 and 80 years.
- Pathological confirmation of AML.
- Use of venetoclax plus chemotherapy as a 1st versus 2nd line treatment.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sohag faculty of medicine Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.